Finasteride — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Benign Prostatic Hyperplasia

• Alfuzosin
• Doxazosin
• Dutasteride
• Sildenafil
• Tadalafil
• Tamsulosin

Other medications in Urology

• Mirabegron
• Oxybutynin
• Oxybutynin Topical
• Phenazopyridine
• Phosphodiesterase 5 inhibitors
• Silodosin
• Solifenacin
• Tadalafil (BPH)

About Finasteride

Finasteride is a widely prescribed medication known for its effectiveness in treating male pattern hair loss and benign prostatic hyperplasia (BPH). Understanding its benefits and accessibility is key to managing these common conditions. At TheDrugClub, we believe essential medications shouldn't break the bank. Finasteride is a medication that plays a significant role in men's health, primarily known for its dual action in addressing both male pattern hair loss and an enlarged prostate. It's a testament to modern pharmacology that one compound can effectively tackle two distinct, yet often related, concerns. ### What Finasteride Treats

Finasteride is approved by the FDA for two main conditions:

1. Male Pattern Hair Loss (Androgenic Alopecia): This common condition leads to thinning hair and baldness, typically starting at the temples and crown. Finasteride helps to slow down hair loss and, in many cases, promotes new hair growth, particularly when treatment is started early. 2. Benign Prostatic Hyperplasia (BPH): Also known as an enlarged prostate, BPH is common

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Finasteride is approved for (FDA label)

Finasteride, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to (1.1) : Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Finasteride (FDA label)

5 mg: Blue colored, circular, biconvex, beveled edged film-coated tablets debossed with ‘E’ on one side and ‘61’ on the other side. 5 mg film-coated tablets (3) .

Source: FDA prescribing information (DailyMed). Set ID: c9a3cb34-9a8e-4538-ab90-32e08d8acc3a. SPL document ID: 18048fb3-c6c5-41ac-a801-4e5995c6258b. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Finasteride (FDA label)

­The drug-related adverse reactions, reported in ≥1% in patients treated with finasteride and greater than in patients treated with placebo over a 4-year study are: impotence, decreased libido, decreased volume of ejaculate, breast enlargement, breast tenderness and rash (6.1) . To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. 4-Year Placebo-Controlled Study ( A Long-Term Efficacy and Safety Study ) In a long-term efficacy and safety study, 1524 patients treated with finasteride and 1516 patients treated with placebo were evaluated for safety over a period of 4 years.

Source: FDA prescribing information (DailyMed). Set ID: c9a3cb34-9a8e-4538-ab90-32e08d8acc3a. SPL document ID: 18048fb3-c6c5-41ac-a801-4e5995c6258b. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Finasteride (FDA label)

Finasteride tablets are contraindicated in the following: Hypersensitivity to any component of this medication. Pregnancy. Finasteride use is contraindicated in females when they are or may potentially be pregnant. Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride. If this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant female should be apprised of the potential hazard to the male fetus. [See also Warnings and Precautions (5.3) , Use in Specific Populations (8.1) , and How Supplied/Storage and Handling (16) .] In female rats, low doses of finasteride administered during pregnancy have produced abnormalities of the external genitalia in male offspring.

Source: FDA prescribing information (DailyMed). Set ID: c9a3cb34-9a8e-4538-ab90-32e08d8acc3a. SPL document ID: 18048fb3-c6c5-41ac-a801-4e5995c6258b. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Finasteride (FDA label)

Finasteride reduces serum prostate specific antigen (PSA) levels by approximately 50%. However, any confirmed increase in PSA while on finasteride may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for men not taking a 5α-reductase inhibitor (5.1) . Finasteride may increase the risk of high-grade prostate cancer (5.2 , 6.1) . Females should not handle crushed or broken finasteride tablets when they are pregnant or may potentially be pregnant due to potential risk to a male fetus (5.3 , 8.1 , 16) . Finasteride is not indicated for use in pediatric patients or females (5.4 , 8.1 , 8.2 , 8.4 , 12.3) . Prior to initiating treatment with finasteride for BPH, consideration should be given to other urological conditions that may cause similar symptoms (5.6) . 5.1 Effects on Prostate Specific Antigen (PSA) and the Use of PSA in Prostate Cancer Detection In clinical studies, finasteride reduced serum PSA concentration by approximately 50% within six months of treatment.

Source: FDA prescribing information (DailyMed). Set ID: c9a3cb34-9a8e-4538-ab90-32e08d8acc3a. SPL document ID: 18048fb3-c6c5-41ac-a801-4e5995c6258b. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Finasteride (FDA label)

7.1 Cytochrome P450-Linked Drug Metabolizing Enzyme System No drug interactions of clinical importance have been identified. Finasteride does not appear to affect the cytochrome P450-linked drug metabolizing enzyme system. Compounds that have been tested in man have included antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found. 7.2 Other Concomitant Therapy Although specific interaction studies were not performed, finasteride was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.

Source: FDA prescribing information (DailyMed). Set ID: c9a3cb34-9a8e-4538-ab90-32e08d8acc3a. SPL document ID: 18048fb3-c6c5-41ac-a801-4e5995c6258b. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.